Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0S9CB
|
|||
| Former ID |
DCL000805
|
|||
| Drug Name |
Flibanserin
|
|||
| Synonyms |
Flibanserin [USAN]; Bimt 17; Bimt-17; 1,3-Dihydro-1-(2-(4-(3-(trifluoromethyl)phenyl)-1-piperazinyl)ethyl)-2H-benzimidazol-2-one; 1-(2-(4-(3-Trifluoromethylphenyl)piperazin-1-yl)ethyl)benzimidazol(1H)-2-one; 1-(2-(4-(alpha,alpha,alpha-Trifluoro-m-tolyl)-1-piperazinyl)ethyl)-2-benzimidazolinone; 1-(2-(4-alpha,alpha,alpha-Trifluoro-m-tolyl)-1-piperazinyl)ethyl)-2-benzimidazolinone; 3-[2-[4-[4-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]-1H-benzimidazol-2-one
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Mood disorder [ICD-11: 6A60-6E23] | Approved | [1], [2] | |
| Female sexual arousal dysfunction [ICD-11: HA01.1; ICD-9: 302.7] | Phase 3 | [1], [3] | ||
| Company |
Boehringer Ingelheim
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C20H21F3N4O
|
|||
| Canonical SMILES |
C1CN(CCN1CCN2C3=CC=CC=C3NC2=O)C4=CC=CC(=C4)C(F)(F)F
|
|||
| InChI |
1S/C20H21F3N4O/c21-20(22,23)15-4-3-5-16(14-15)26-11-8-25(9-12-26)10-13-27-18-7-2-1-6-17(18)24-19(27)28/h1-7,14H,8-13H2,(H,24,28)
|
|||
| InChIKey |
PPRRDFIXUUSXRA-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 167933-07-5
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
12014794, 14805189, 17194769, 17396748, 43529631, 50502868, 57371851, 85210078, 103527157, 109693339, 114787677, 128950413, 131301443, 134339283, 135083608, 137061555, 137255793, 142466182, 163884610, 164833020, 175426897, 175437953, 198977406, 198991596, 203355698, 226597215, 244182240, 249565862, 252160198
|
|||
| ChEBI ID |
CHEBI:90865
|
|||
| ADReCS Drug ID | BADD_D00904 | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8182). | |||
| REF 2 | Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651. | |||
| REF 3 | Designing drugs for the treatment of female sexual dysfunction. Drug Discov Today. 2007 Sep;12(17-18):757-66. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.